NCT07281989 Sound Stops Stress Study: Evaluating the WAVwatch Effect
| NCT ID | NCT07281989 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Efforia, Inc |
| Condition | Stress |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-08-25 |
| Primary Completion | 2026-08-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-08-25 with a primary completion date of 2026-08-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Sound Off Stress Study seeks to discover if WAVwatch 2.0-a sleek, wearable sound frequency device-can support mental harmony.
Eligibility Criteria
Inclusion Criteria: * Can read and understand English. * US resident. * Willing and able to follow the requirements of the protocol. Exclusion Criteria: * Individuals with skin sensitivities * Individuals with auditory conditions * Individuals with severe anxiety or mental health disorders * Pregnancy * Individuals prone to irritation or frustration
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07281989 clinical trial?
This trial is open to participants of all sexes, studying Stress. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07281989 currently recruiting?
Yes, NCT07281989 is actively recruiting participants. Contact the research team at help@efforia.com for enrollment information.
Where is the NCT07281989 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT07281989 clinical trial?
NCT07281989 is sponsored by Efforia, Inc. The trial plans to enroll 100 participants.